u/marta_vanhecke

the glucagon component is why the metabolic story reads differently

Sent a vial to Medutest out of curiosity. Result was 99.6% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.

liver_enzyme_liz is right about the escalation being the variable.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

That is a report count, not a test count. The table lists both and they are very different numbers.

Fixing my own comment above: I said 5 orders and it is 10. The pattern is the same, the count was wrong.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Agreed. The denial letter tells you which criterion failed, and answering that specific criterion is the entire job.

deadlines run from the letter date, not from when you opened it

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

Agreed on buying small first. The cost of a test is small next to the cost of committing to a supplier you have not checked.

Small fix — three receptors, not two.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

Inter-lab variance on this assay runs a point or two either way. Two services disagreeing by that much is agreement, not a discrepancy, and treating it otherwise starts pointless arguments.

Inter-lab variance on this assay runs a point or two either way. Two services disagreeing by that much is agreement, not a discrepancy, and treating it otherwise starts pointless arguments.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

That reads as a recommendation and the source pages deliberately are not. They are a record you use to make your own decision.

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

Prior authorisation criteria are republished each plan year.

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

That is a report count, not a test count. The table lists both and they are very different numbers.

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Peer-to-peer took fifteen minutes and resolved something a written appeal had been sitting on for a month.

the energy-expenditure story is mechanistically interesting and clinically unproven

Did you ask for the batch-specific certificate, or the generic one?

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Yes. Written, always, even when they tell you a phone call is sufficient.

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

the denial letter names the criterion, start there

Six orders across two years from SSA. Same packaging, same paperwork, same lead time. The most boring supplier relationship I have and I mean that as praise.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

the phase 2 numbers were striking and they were also 48 weeks in a small population